Key clinical point: Long-term entecavir therapy was safe and produced a superior rate of sustained virologic response, compared with other hepatitis B virus nucleoside or nucleotide analogues.
Major finding: The two trial arms did not significantly differ in time-to-event analyses of malignant neoplasms, liver-related hepatitis B virus disease progression, and death.
Study details: A global randomized clinical trial of 12,522 adults with chronic hepatitis B virus infection.
Disclosures: Bristol-Myers Squibb designed the study, performed statistical analyses, and funded the study and manuscript preparation. The Ministry of Science and Technology of China and the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program provided partial support. Dr. Hou disclosed grants and personal fees from Bristol-Myers Squibb, GlaxoSmithKline, and Novartis. Several coinvestigators also disclosed ties to Bristol-Myers Squibb and to several other pharmaceutical companies.
Hou J-L et al. Clin Gastroenterol Hepatol. 2019 Jul 12. doi 10.1016/j.cgh.2019.07.010.